La chaîne d'options affiche les données clés des options sur actions de DiaMedica Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour DiaMedica Therapeutics..

DiaMedica Therapeutics (NASDAQ:DMAC) Stock, Chaîne d'Options

DiaMedica Therapeutics

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

DiaMedica Therapeutics Inc. - Common Stock

DiaMedica Therapeutics Inc

Press Releases

DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025

DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes

DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer

DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline

DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement

DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025

DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer

DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

DiaMedica Therapeutics to Participate in Cantor Global Healthcare Conference

DiaMedica Therapeutics to Participate in Upcoming Investor Conferences

DMAC

Abeona Therapeutics

Absci

ADC Therapeutics

Astria Therapeutics

Aura Biosciences

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Benitec Biopharma

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

CytomX Therapeutics

Bright Minds Biosciences Inc. - common stock

Bright Minds Biosciences

Design Therapeutics

ETHZilla

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

I-MAB

Immuneering Corporation - Class A Common Stock

Immuneering

Inhibrx Biosciences

Kamada

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Ocugen

ProKidney Corp. - Class A Ordinary Shares

ProKidney

PureTech Health plc - American Depositary Shares

PureTech Health

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Tectonic Therapeutic, Inc. - Common Stock

Comments

DiaMedica Therapeutics

DiaMedica Therapeutics (DMAC) Options

DiaMedica Therapeutics (NASDAQ:DMAC) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL